U.S. markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
213.61-1.44 (-0.67%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close215.05
Bid213.50 x 800
Ask213.67 x 900
Day's Range213.20 - 215.30
52 Week Range210.28 - 276.69
Avg. Volume2,426,890
Market Cap121.299B
Beta (5Y Monthly)0.67
PE Ratio (TTM)21.66
EPS (TTM)9.86
Earnings DateOct 26, 2021 - Nov 01, 2021
Forward Dividend & Yield7.04 (3.30%)
Ex-Dividend DateAug 16, 2021
1y Target Est248.18
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-8% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amgen Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more
  • PR Newswire

    FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

    Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.

  • PR Newswire

    Amgen To Present At The 2021 Cantor Global Healthcare Conference

    Amgen (NASDAQ:AMGN) will present at the Cantor Global Healthcare Conference at 2:00 p.m. ET on Monday, Sept. 27, 2021. Susan Sweeney, senior vice president, Global Marketing, Access and Capabilities and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

  • PR Newswire

    Amgen Releases 8th Edition of Biosimilar Trends Report

    Amgen (NASDAQ: AMGN) today released the 8th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare system. To access the full report, visit: www.amgenbiosimilars.com/commitment/trends-report.